Cairns R, Brown JA, Gunja N, Buckley NA. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre. Int J Drug Policy 2017;43:74–82. https://www.ncbi.nlm.nih.gov/pubmed/28343112
Dassanayake TL, Jones AL, Michie PT, Carter GL, McElduff P, Stokes BJ, et al. Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: a self-controlled case series study in Australia. CNS Drugs 2012;26(3):269–76. https://www.ncbi.nlm.nih.gov/pubmed/22329565
Dassanayake TL, Michie PT, Jones AL, Mallard T, Whyte IM, Carter GL. Cognitive skills underlying driving in patients discharged following self-poisoning with central nervous system depressant drugs. Traffic Inj Prev 2012;13(5):450–7. https://www.ncbi.nlm.nih.gov/pubmed/22931174
Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013;108(3):534–44. https://www.ncbi.nlm.nih.gov/pubmed/22971158
Sweeney B, Talebi S, Toro D, Gonzalez K, Menoscal JP, Shaw R, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med 2016;34(1):121 e1–2. https://www.ncbi.nlm.nih.gov/pubmed/26143311
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 2016;54(1):1–13. https://www.ncbi.nlm.nih.gov/pubmed/26567470
